Rx Pricing, Rebating Should Be Back To Business As Usual In 2020, PBMs Say
Executive Summary
Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.
You may also be interested in...
PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.
GAO Report On Part D May Dampen Congressional Enthusiasm For POS Rebates
Legislation redirecting manufacturer rebates on prescription drugs to the point of sale could face an uphill battle following report’s description of the way rebates lower costs in Medicare Part D.
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.